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Objective: To examine cognitive deficits and associated brain activity in fragile
X-associated tremor/ataxia syndrome (FXTAS) patients with parkinsonism (FXTp+), in
relation to FXTAS patients without parkinsonism (FXTp-), and normal elderly controls
(NC).
Methods: Retrospective reviews were performed in 65 FXTAS patients who participated
in the event-related brain potential (ERP) study and also had either a videotaped
neurological examination or a neurological examination for extrapyramidal signs.
Parkinsonism was defined as having bradykinesia with at least one of the following:
rest tremor, postural instability, hypermyotonia, or rigidity. Eleven FXTp+ patients were
identified and compared to 11 matched FXTp- and 11 NC. Main ERP measures included
the N400 congruity effect, N400 repetition effect, and the late positive component (LPC)
repetition effect.
Results: When compared with FXTp- and NC, the FXTp+ group showed more severe
deficits in executive function, cued-recall, recognition memory, along with a significantly
reduced N400 repetition effect (thought to index semantic processing and verbal
learning/memory) which was correlated with poorer verbal memory. Across all patients,
FMR1 mRNA levels were inversely correlated with delayed recall on the California Verbal
Learning Test (CVLT).
Interpretation: The findings of more prominent executive dysfunction and verbal
learning/memory deficits in FXTp+ than FXTp- are consistent with findings in Parkinson’s
disease (PD), and may indicate that concomitant and/or synergistic pathogenetic
mechanisms associated with PD play a role in FXTAS. These results have implications
not only for understanding the cognitive impairments associated with the parkinsonism
subtype of FXTAS, but also for the development of new interventions for these patients.
Keywords: FMR1 premutation, cognition, event-related potential (ERP), parkinsonism, semantic processing
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INTRODUCTION
Fragile X-associated tremor/ataxia syndrome (FXTAS) is a
late-onset neurodegenerative disorder that primarily affects
carriers of premutation CGG repeat expansions (range: 55–
200) in the fragile X mental retardation 1 (FMR1) gene
(Hagerman et al., 2001). The FMR1 premutation produces
elevated FMR1 mRNA levels and leads to RNA gain-of-
function toxicity, thought to be a fundamental mechanism
of pathogenesis in FXTAS (Tassone et al., 2000; Hagerman
and Hagerman, 2016). Neuropathological studies in FXTAS
have revealed intranuclear FMR1 mRNA-containing inclusions
in neurons and astrocytes throughout the central nervous
system (Greco et al., 2002). Radiological anomalies in FXTAS
include brain atrophy and white matter diseases frequently
found in the middle cerebellar peduncles (the MCP sign),
the periventricular area, and the corpus callosum. Phenotypic
manifestations of FXTAS are characterized by intention tremor,
cerebellar ataxia, and cognitive decline. Other common clinical
presentations of FXTAS include parkinsonian features (Hall
et al., 2009) (a minor diagnostic criterion for FXTAS) and
polyneuropathy (Hagerman and Hagerman, 2013, 2016). Patients
with FXTAS have been found to have increased prevalence
of parkinsonian features including bradykinesia (57%), rest
tremor (26%), and postural instability (42%) (Niu et al.,
2014). In that study, bradykinesia scores in those FXTAS
patients were significantly correlated with both FMR1 mRNA
level and FXTAS clinical stage. Some of the patients with
concomitant diagnoses of FXTAS and Parkinson’s disease
(PD) or dual pathologies of the two disorders showed
clinical benefits from dopaminergic treatment, whereas some
displayed dopamine deficiency on SPECT imaging with an
absence of response to L-dopa (De Pablo-Fernandez et al.,
2015).
Cognitive deficits in FXTAS are well-established as
impairments in executive function, short-term memory,
and visuospatial processing. Milder cognitive difficulties in
these same domains have been documented in premutation
carriers asymptomatic of FXTAS (Grigsby et al., 2014; Wheeler
et al., 2014). For 11 PD patients carrying GZ and lower
end premutation alleles (41–85 repeats), Trost et al. (2014)
reported significant correlations of white matter hyperintensities
on MRI with both CGG repeats and neuropsychological
test scores of general ability, working memory, and verbal
learning. However, cognitive profiles of a subtype of FXTAS
with parkinsonism (defined as having bradykinesia and at
least one other main parkinsonian feature) remains largely
unknown. As mentioned previously, Niu et al. (2014) performed
a retrospective study using videotaped neurological exam data
in a cohort of 38 patients with FXTAS, but their analyses
were focused on parkinsonian motor features among these
patients. In the current study, neuropsychological tests and
event-related brain potentials (ERPs) were employed to examine
cognitive functions and associated electrophysiological indexes
in FXTAS patients with parkinsonism, in relation to FXTAS
patients without parkinsonism and age matched healthy
controls.
PATIENTS AND METHODS
Participants
Retrospective reviews of data from 65 FXTAS patients who
participated in the ERP study and also have either a videotaped
neurological examination or a neurological examination
performed by J.M.O for extrapyramidal signs. Parkinsonism
was defined as bradykinesia with at least one of the following:
rest tremor, postural instability, or hypermyotonia (in the
videotaped cases), or rigidity (as assessed in neurological exam
by J.M.O) (Hughes et al., 1992). Participants had provided
written informed consent for a study protocol approved by
the University of California Davis Institutional Review Board.
There were 14 FXTAS patients with parkinsonism (FXTp+)
identified by neurologists X-H.W. and J.M.O., two of which had
unusable EEG data due to excessive artifacts and one of which
was a non-native English speaker and thus did not complete
the ERP word repetition experiment. Therefore, 11 FXTAS
patients were included in the final sample of FXTp+. 11 FXTAS
patients without parkinsonian symptoms (FXTp-) were selected
to match FXTp+ patients in a one-on-one fashion based on
demographics (age, education) and MMSE score. In addition
11 demographically matched normal controls (NC) were also
analyzed.
FMR1 CGG repeat length and FMR1 mRNA level were
quantified following procedures described elsewhere (Tassone
et al., 2000, 2008). All patients had received a FXTAS diagnosis
according to published criteria for probable or possible FXTAS
(Jacquemont et al., 2003). Demographics and genetic measures
are summarized in Table 1.
Neuropsychological Testing
Each subject underwent extensive neuropsychological
evaluations. The Mini-mental state examination (MMSE)
(Folstein et al., 1975; Folstein, 1990) was used as a measure
of global cognitive abilities. Executive function was evaluated
using the Stroop Color and Word Test (Stroop) (Spreen, 1998),
Behavioral Dyscontrol Scale-2 (BDS-2) (Grigsby, 1996) and
controlled oral word association test (COWAT) (Desrosiers
and Kavanagh, 1987). The color-word component of the Stroop
Test is a measure of cognitive inhibition. The BDS-2 provides a
valid and reliable measure of behavioral self-regulation involving
intentional control of voluntary motor behavior. The COWAT is
a measure of verbal fluency, widely considered to be a component
of executive function. Verbal memory was assessed with the
California Verbal Learning Test (CVLT) (Delis et al., 1987).
EEG/ERP Experiment
Thirty-two-channel EEG recordings were obtained during a
cross-modal category judgment/word repetition paradigm in
which semantically congruous category-exemplar (e.g., “a type
of meat” – “chicken”) or incongruous nouns (e.g., “a part of
the day” – “sapling”) pairs were presented and then repeated
∼10–140 s later. Category statements were read aloud, each
followed ∼1 s later by a visually presented target word presented
for 300 ms. Subjects were instructed to wait 3 s following the
Frontiers in Genetics | www.frontiersin.org 2 September 2018 | Volume 9 | Article 327
fgene-09-00327 September 14, 2018 Time: 9:14 # 3
Wang et al. N400 in FXTAS With Parkinsonism
appearance of the target, then say the perceived word aloud, and
use “yes/no” to indicate whether or not it was an exemplar of the
defined category.
Participants were assigned to one of the three counterbalanced
stimulus lists, which consist of 36 congruous category statement-
target pairs presented once, 36 presented twice, 36 presented
three times, and the equal numbers of incongruous stimuli in
the same repetition patterns. In the total of 432 trials, 50% of the
stimuli were congruous while 50% were incongruous, and 50%
were new, while 50% were repeats. A repeated target word always
followed the same category statement as in the first presentation.
For stimuli repeated once, the lag between the first and second
presentations was 10–40 s. For stimuli repeated twice, the lag for
both second and third presentations was ∼100–140 s after the
first presentation.
The EEG session lasted slightly over 20 min. More details of
the ERP word repetition paradigm in FXTAS, including the EEG
montage used, were described in previously published studies
(Olichney et al., 2010; Yang et al., 2014b).
After the EEG recordings were completed, three unanticipated
paper and pencil memory tests (free recall, cued recall, and then a
multiple-choice recognition questionnaire) for the experimental
stimuli used in the ERP study were administered.
Data Analysis
EEG trials contaminated by eye blinks or movements, excessive
muscle activity or amplifier blocking were rejected. By averaging
artifact-free epochs of each condition, separate ERP waveforms
were obtained for new congruous and incongruous target words,
as well as for repeated congruous and incongruous target words.
Mean ERP amplitude, peak amplitude and peak latency of
N400 congruity effect (new congruous vs. incongruous words),
N400 repetition effect (new vs. old incongruous words), and
late positive component (LPC) repetition effect (new vs. old
congruous words) were quantified. Repeated-measures ANOVAs
were performed on each of the three main ERP measures
from 24 scalp electrodes (excluding Fp1 and Fp2 because of
their vulnerability to muscle activity; excluding POz and PO7
because of large electrode artifacts for two FXTAS patients).
The Greenhouse-Geisser correction was used whenever the
assumption of sphericity was violated. Post hoc tests were
followed when warranted and Tukey’s multiple comparison test
was used. P-values of < 0.05 were considered as significant for
group comparisons.
Linear correlations between ERP measures, molecular/genetic
measures, neuropsychological test scores, and subsequent
memory scores for ERP experimental stimuli were examined.
Pearson correlations were considered significant if p ≤ 0.05.
RESULTS
Genetic and Molecular Testing
As expected, in all 22 patients with FXTAS, CGG repeats
were significantly expanded [F(2,27) = 17.07, p < 0.0001] and
FMR1 mRNA levels were significantly elevated [t(1,18) = 41.96,
p < 0.0001] when compared to normal controls. However, no
significant differences on FMR1 CGG repeats and mRNA levels
were found between patients with and without parkinsonism
(Table 1).
Behavioral Results
Table 2 summarizes neuropsychological test scores for the three
groups. Compared to normal controls, the combined patient
group of FXTp+ and FXTp− demonstrated poorer performance
on global cognition (MMSE, p = 0.02), executive function
(BDS-2, p = 0.02), inhibition (Stroop, p = 0.02), and verbal
learning/acquisition (CVLT list A trials 1–5, p = 0.048). In
contrast to FXTp−, the FXTp+ group was found to have more
severe deficits in executive function as measured by BDS-2 and
COWAT (p’s = 0.01), as well as a poorer memory for experimental
stimuli (cued-recall: p = 0.03; multiple-choice: p = 0.05).
ERP Results
Repetition of Incongruous Words
The grand-average ERPs and topography maps in Figure 1
present the N400 word repetition effect (the difference between
ERPs to initial and repeated presentations of incongruous target
words).
Repeated measures ANOVA of the N400 mean amplitude
between 300 and 550 ms after the onset of target words revealed
a significant main effect of repetition (F = 29.64, p < 0.0001,
η2 = 0.5), confirming the presence of N400 repetition effect across
all participants. ANOVA also found a significant interaction
TABLE 1 | Demographics and genetic-molecular measures (Mean ± SD) NC.
NC (n = 11) FXTp− (n = 11) FXTp+ (n = 11) P
Age 63.7 ± 7.7 63.7 ± 9.2 62.2 ± 7.7 0.88
Education (years) 15.72 ± 1.85 14.55 ± 3.05 15.09 ± 2.88 0.58
Females (N) 5 5 5
Left-handed (N) 1 1 1
FXTAS stage – 3.10 ± 0.88 3.27 ± 0.65 0.80#
CGG repeats 32.43 ± 7.83 96.18 ± 33.57 84.75 ± 14.65 0.51#
FMR1 mRNA 1.42 ± 0.38 2.99 ± 0.62 3.05 ± 0.52 0.98#
(n = 20) (n = 6) (n = 7) (n = 7)
NC, normal controls; FXTp-, FXTAS patients without parkinsonism; FXTp+, FXTAS patients with parkinsonism. FXTAS disease stages were based on the functioning levels
as defined in Jacquemont et al. (2003). # Indicates p-values from comparisons between two FXTAS subgroups.
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TABLE 2 | Neuropsychological test scores compare (Mean ± SD).
NC (n = 11) ∗P FXTp− (n = 11) FXTp+ (n = 11) #P
Global abilities
MMSE 28.55 ± 1.04 0.02 27.45 ± 1.37 27.00 ± 2.00 0.54
Executive function
COWAT 44.11 ± 10.5 0.33 46.00 ± 16.33 28.33 ± 11.86 0.01
BDS-2 19.75 ± 4.43 0.02 17.30 ± 3.89 12.22 ± 3.73 0.01
Stroop 54.85 ± 12.1 0.02 47.00 ± 6.16 37.89 ± 12.49 0.08
Verbal memory
CVLT list A, trials 1–5 52.63 ± 7.74 0.048 46.73 ± 12.84 36.67 ± 12.21 0.09
CVLT short delay free recall 10.63 ± 2.97 0.18 9.36 ± 3.80 7.56 ± 3.84 0.31
CVLT long delay free recall 10.75 ± 2.76 0.09 9.09 ± 4.28 6.66 ± 3.61 0.19
CVLT short delay cue-recall 11.5 ± 2.51 0.13 9.73 ± 3.23 9.33 ± 3.28 0.79
CVLT long delay cue-recall 12.00 ± 2.39 0.11 10.09 ± 3.81 9.22 ± 3.60 0.61
CVLT long delay discriminability 95.76 ± 2.82 0.08 85.56 ± 15.60 89.88 ± 8.25 0.46
Subsequent memory (for ERP experimental stimuli)
Free recall 19.55 ± 11.83 0.07 12.45 ± 8.72 11.89 ± 11.47 0.90
Cued-recall 18.00 ± 3.16 0.08 17.27 ± 1.79 13.70 ± 4.69 0.03
Multiple choice 19.50 ± 1.58 0.46 20.18 ± 1.94 16.50 ± 5.50 0.05
BDS-2, Behavioral Dyscontrol Scale-2; COWAT, Controlled Oral Word Association Test; CVLT, California Verbal Learning Test. ∗P, NC vs. all FXTAS patients; #P, FXTp−
vs. FXTp+ subgroups. P’s < 0.05 are bolded above.
between electrode and group (F = 2.84, p = 0.019), and a
marginally significant interaction between repetition and group
(F = 3.26, p = 0.052). Further analysis focusing on a lateral-
posterior (where the N400 repetition effect is most reliably
obtained in normal subjects) cluster of 12 electrodes (41L/41R,
WL/WR, CP1/CP2, T5/T6, P3/4, O1/O2) showed a significant
interaction between repetition and group (F = 4.39, p = 0.02,
η2 = 0.23). Post hoc group comparisons indicated that FXTp+
group has significantly reduced N400 repetition effect amplitude
(Mean = −0.26 µV, SD = 1.53) compared to both normal
controls (Mean = −1.47 µV, SD = 1.27, p = 0.036) and
FXTp− group (Mean = −1.43 µV, SD = 1.24, p = 0.044).
No significant group difference was detected between FXTp−
group and normal controls (p = 0.99). To test if the group
difference in the N400 repetition effect was mediated by the
potential confounds of sex, FMR1 mRNA level (normalized
in relation to the mean value of the control group), or the
CVLT measures of learning and memory, additional ANCOVA
models were tested. These analyses showed that significant
intergroup differences persisted after correcting for sex (F = 4.34,
p = 0.02) or CVLT long delay cued recall (F = 4.40, p = 0.02),
but narrowly missed statistical significance after correcting for
CVLT learning of List A, trial 1–5 (F = 2.89, p = 0.075) or
FMR1 mRNA (F = 2.58, p = 0.10; data only available for
n = 20).
No significant group differences were found for latency
measures of N400 repetition effect.
Repetition of Congruous Words
Figure 2 shows word repetition effect of the LPC (i.e., the
difference between ERPs to initial and repeated presentations of
congruous target words).
Repeated measures ANOVA of the LPC mean amplitudes
between 300 and 800 ms after the onset of target words
demonstrated a significant main effect of repetition (F = 13.75,
p = 0.0008, η2 = 0.31), confirming the presence of an LPC
repetition effect across all subjects. Despite the seemingly
stronger positivities shown in the topographic maps of normal
controls relative to patients, ANOVA of the LPC repetition effect
amplitudes found no statistically significant group differences
in the 300–550 ms time window (F = 1.4, p = 0.26) or in the
550–800 ms time window (F = 1.83, p = 0.18). No significant
group differences were found for latency measures of LPC
repetition effects.
N400 Congruity Effect to New Words
Figure 3 displays the N400 congruity effect (i.e., the difference
between ERPs to initial presentations of congruous vs.
incongruous target words).
Repeated measures ANOVA of the N400 mean amplitudes
between 300 and 550 ms revealed a significant main effect
of congruity across all participants (F = 22.12, p < 0.0001,
η2 = 0.42), confirming the presence of the N400 congruity
effect. Though the topographic maps seem to visually show
more prominent negativities in normal controls relative to
patients, ANOVA of the N400 congruity effect amplitudes found
no statistically significant differences among the three groups
(F = 1.51, p = 0.24).
Correlational Results
Correlational tests revealed that increased N400 repetition
effect amplitudes (averaged across the five right temporo-
parietal electrodes Wr, T6, CP2, P4, and O2) were significantly
correlated with higher scores on subsequent cued-recall (r = 0.61,
p = 0.0002) and multiple choice recognition (r = 0.46, p = 0.009)
for the congruous target words across all 33 participants
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FIGURE 1 | The N400 repetition effect. Upper: topographical maps of the N400 repetition effect (new–old incongruous words). Lower: grand average ERPs to initial
(dotted line) and repeated (solid line) presentations of incongruous words, at eight selected temporal-posterior electrodes.
(Table 3). To make positive correlation coefficients represent
positive associations, N400 repetition effect used in correlational
analysis was calculated by subtracting N400 to incongruous
words from N400 to congruous words. Across all subjects, the
association between larger N400 repetition effect amplitudes
and higher verbal memory scores was also supported by the
marginally significant correlations between N400 repetition effect
and free recall scores for the congruous target words (r = 0.37,
p = 0.04), learning/acquisition as measured by CVLT list A trials
1–5 (r = 0.44, p = 0.02), and CVLT long delay cued recall
Frontiers in Genetics | www.frontiersin.org 5 September 2018 | Volume 9 | Article 327
fgene-09-00327 September 14, 2018 Time: 9:14 # 6
Wang et al. N400 in FXTAS With Parkinsonism
FIGURE 2 | The LPC/P600 repetition effect. Columns to the left: grand average ERPs to initial (dotted line) and repeated (solid line) presentations of congruous
new – old words at electrodes Cz (midline central) and Pz (midline parietal). Right column: topographical maps of the LCP/P600 repetition effect.
FIGURE 3 | The N400 congruity effect. Columns to the left: grand average ERPs to incongruous initial (dotted line) and congruous initial (solid line) presentations of
incongruous – congruous new words at posterior temporal electrodes T5 and T6. Right column: topographical maps of the N400 congruity effect.
(r = 0.42, p = 0.03). Similar magnitude correlations were found
within all 22 FXTAS patients (Table 3), but the correlations with
CVLT measures both narrowly missed the threshold for statistical
significance (p’s = 0.06 and 0.08). No correlations between
N400 repetition effect and executive function, as measured by
the BDS-2, were found. FMR1 mRNA levels across all FXTAS
patients (n = 14 had mRNA data) were inversely correlated
with delayed recall memory as measured by CVLT (short delay
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TABLE 3 | Linear correlation coefficients between N400 repetition effect amplitude and neuropsychological test scores.
All subjects Two patient groups FXTp− FXTp+
r P r P r P r P
BDS-2 0.14 0.47 0.29 0.23 −0.47 0.173 0.47 0.21
CVLT-long delay cued 0.42 0.03∗ 0.40 0.08 0.28 0.41 0.66 0.054
CVLT list A, trials 1–5 0.44 0.02∗ 0.42 0.06 −0.07 0.85 0.56 0.12
Free recall 0.37 0.04∗ 0.56 0.01∗ 0.78 0.0049∗∗ 0.50 0.17
Cued recall 0.61 0.0002∗∗∗ 0.69 0.0005∗∗∗ 0.88 0.0003∗∗∗ 0.55 0.10
Multiple choice 0.46 0.009∗ 0.51 0.02∗ 0.32 0.33 0.45 0.19
The N400 repetition effect here is a composite score based on the mean amplitude across five posterior electrodes (Cp2, P4, Wr, T6, and O2). FXTp-, FXTAS patients
without parkinsonism; FXTp+, FXTAS patients with parkinsonism. ∗P < 0.05; ∗∗P < 0.005; ∗∗∗P < 0.001.
free recall: r = −0.77, p = 0.002; short delay cued recall:
r = −0.71, p = 0.006; long delay cued recall: r = −0.72,
p = 0.005), but not with N400 repetition effect amplitude (r = 0.22,
p = 0.44).
DISCUSSION
Although parkinsonian features are common in FXTAS and
represent a minor diagnostic criterion for FXTAS, characteristics
and trajectories of cognitive functioning in a subtype of
FXTAS with parkinsonism (defined as having a FXTAS
diagnosis along with bradykinesia and at least one other main
parkinsonian feature) remains largely understudied. The current
study examined cognitive abilities in FXTAS patients with
(FXTp+) and without parkinsonism (FXTp−) using an ERP
word repetition experiment and neuropsychological testing. The
results showed that, when compared with FXTp− and NC, the
FXTp+ group demonstrated more severe deficits in executive
function and verbal memory, along with a significantly reduced
N400 repetition effect which was correlated with verbal memory
both for target words used in the ERP experiment and on CVLT.
Across all FXTAS patients, FMR1 mRNA levels were inversely
correlated with delayed recalls on CVLT. This study represents
the first to characterize both cognitive and electrophysiological
profiles in FXTAS with and without parkinsonism.
Executive dysfunction and verbal learning/acquisition
deterioration have been shown to be the primary cognitive
deficits in PD patients without dementia. Muslimovic et al.
(2005) examined 115 newly diagnosed PD patients and found
that cognitive impairments in these patients are mediated
by immediate memory and executive function, and that the
largest effect size was found on immediate verbal memory on
the Rey Auditory Verbal Learning Test (RAVLT; trials 1–5).
(Muslimovic et al., 2005) Aarsland et al. (2009) investigated
196 drug-naïve PD patients and obtained largest effect size
for verbal memory (both immediate and delayed) on CVLT-2.
The present findings of more prominent executive dysfunction
and verbal memory deficits in FXTp+ than FXTp− are thus
consistent with those in PD patients, and may indicate that
concomitant and/or synergistic pathogenetic mechanisms
associated with PD play a role in neurodegeneration among
patients with FXTAS. As mentioned above, studies in carriers
of slightly expanded CGG repeat FMR1 alleles with a diagnosis
of PD have observed more severe cognitive deficits in general
ability, memory, and attention domains when compared with
their disease controls with PD (Loesch et al., 2011; Trost et al.,
2014). Although there has been controversy regarding the neural
substrates of executive function, lesion data and neuroimaging
studies generally agree that, broadly speaking, prefrontal cortex
is the key region supporting executive function. Interestingly,
decreased functional connectivities between right prefrontal
regions and right hippocampus were observed in a group of male
premutation carriers without FXTAS during a working memory
task (Wang et al., 2012).
The N400 effect is a well-established electrophysiological
index of semantic priming and semantic processing load. Yang
et al. (2014a) have found that the N400 repetition effect amplitude
is the strongest predictor of the CVLT short delay cued recall
score in patients with FXTAS and was correlated significantly
with all 6 CVLT measures of verbal learning and memory in
the FXTAS group, but not in a group with prodromal/early
AD. These authors suggested that the N400 repetition effect,
shown to primarily originate from temporal neocortex (Nobre
et al., 1994; Halgren et al., 2002), has substantial association with
learning/acquisition and short delayed recall, and is sensitive to
memory dysfunction in FXTAS.
The pathophysiological mechanisms underlying
parkinsonism in FXTAS remains elusive. Loesch et al. (2011)
found reduced dehydrogenase subunit 1 mitochondrial gene in
whole blood in carriers compared to disease controls with typical
and atypical PD. The authors thus suggested the involvement of
mitochondrial dysfunction in the development of parkinsonism
in carriers of the FMR1 gray-zone and premutation alleles.
Hagerman and Hagerman (2016) indicated that the pathological
development of PD in FXTAS might also be facilitated by
extracellular deposition of iron. Another pathogenic mechanism
to consider is the proteasomal degradation pathway that was
found to be affected in both FXTAS and PD (Moore et al.,
2003; Iwahashi et al., 2006). Finally, studies have found that
several autopsied cases with FXTAS also had superimposed
α-synuclein containing Lewy body pathology (Greco et al.,
2002; De Pablo-Fernandez et al., 2015). How these possible
mechanisms contribute to the cognitive and electrophysiological
phenotypes observed in FXTp+ require substantial further
investigations.
Frontiers in Genetics | www.frontiersin.org 7 September 2018 | Volume 9 | Article 327
fgene-09-00327 September 14, 2018 Time: 9:14 # 8
Wang et al. N400 in FXTAS With Parkinsonism
CONCLUSION
To conclude, when compared to both normal elderly controls
and FXTAS patients without parkinsonism, FXTAS patients with
parkinsonism present more severe deficits in executive function
and verbal learning, as well as a significantly reduced N400
repetition effect which was inversely correlated with verbal
learning and verbal memory abilities. It has been reported that,
in the first randomized controlled clinical trial for FXTAS, the
N400 ERP repetition effect was improved after 12 months of
treatment with the uncompetitive NMDA antagonist memantine,
and the N400 improvement was correlated with better cued-
recall of the experimental verbal stimuli (Yang et al., 2014b).
Therefore, the current findings have implications not only for
understanding the cognitive impairments associated with the
parkinsonism subtype of FXTAS, but also for the development
and validation of new pharmaceutical (e.g., memantine in
combination with L-dopa) and behavioral intervention for these
cognitive impairments. Study limitations include limited sample
sizes, incomplete data of some measures (e.g., FMR1 mRNA
level), and lack of neurophysiological confirmation of clinical
diagnosis. Replication of these results in independent samples
will be important as will be further studies to characterize
cognition, biomarkers, and neuropathology in larger samples of
FXTAS patients with Parkinsonism.
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